Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells

National Medical Journal of China

Volumn 92, Issue 16, 2012, Pages 1100-1103

  Zang, Mei Rong ^a   Li, Fei ^a   An, Gang ^a   Xie, Zhen Qing ^a   Li, Chang Hong ^a   Yu, Zhen ^a   Xu, Yan ^a   Qiu, Lu Gui ^a   Hao, Mu ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Bone marrow stromal cells; Drug resistance, neoplasm; MicroRNAs; Multiple myeloma

Indexed keywords

BORTEZOMIB; INTERLEUKIN 6; MELPHALAN; MICRORNA 15A; MICRORNA 16; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; STROMA CELL;

BONE MARROW CELLS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MICRORNAS; MULTIPLE MYELOMA; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 84868297068     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2012.16.006     Document Type: Article

References (17)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood, 2008, 111: 2962-2972.
2. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell, 2009, 4: 226-235.
3. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat, 2007, 10: 59-67.
4. Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res, 2009, 69: 2996-3003.
5. +, Arf-null lymphoblastic leukemia. Genes Dev, 2007, 21: 2283-2287.
6. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res, 2008, 14: 2519-2526.
7. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 2009, 23: 10-24.
8. Roorda BD, ter Elst A, Kamps WA, et al. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol, 2009, 69: 187-198.
9. Bisping G, Wenning D, Kropff M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t (4; 14) myeloma. Clin Cancer Res, 2009, 15: 520-531.
10. Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol, 2011, 94: 334-343.
11. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics, 2009, 10: 399-416.
12. Lima RT, Busacca S, Almeida GM, et al. MicroRN A regulation of core apoptosis pathways in cancer. Eur J Cancer, 2011, 47: 163-174.
13. Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A, 2010, 107: 21098-21103.
14. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A, 2002, 99: 15524-15529.
15. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A, 2005, 102: 13944-13949.
16. Paul E, Sutlu T, Deneberg S, et al. Impact of chromosome 13 deletion and plasma cell load on long-tern survival of patients with multiple myeloma undergoing autologons transplantation. Oncol Rep, 2009, 22: 137-142.
17. 2010, 31: 680-683.